A multicenter, open-label, parallel-group, randomized, flexible dose study to evaluate the safety and tolerability of switching from existing atypical antipsychotics to bifeprunox in subjects with schizophrenia or schizoaffective disorder.

Trial Profile

A multicenter, open-label, parallel-group, randomized, flexible dose study to evaluate the safety and tolerability of switching from existing atypical antipsychotics to bifeprunox in subjects with schizophrenia or schizoaffective disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Bifeprunox (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 26 Apr 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 21 Mar 2008 Actual patient number added from ClinicalTrials.gov.
    • 21 Mar 2008 Status changed from suspended to discontinued, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top